[State of the art: Direct oral anticoagulants and transfusion]. / État de l'art : nouveaux anticoagulants et transfusion.
Transfus Clin Biol
; 24(3): 154-159, 2017 Sep.
Article
em Fr
| MEDLINE
| ID: mdl-28673500
ABSTRACT
Direct oral anticoagulants (DOAC) are indicated for stroke prevention in atrial fibrillation and for the prevention and treatment of venous thromboembolism. As any anticoagulant, they are associated with a bleeding risk. Management of DOAC-induced bleeding is challenging. Idarucizumab, antidote for dabigatran, is currently available and is part of the therapeutic strategy, whereas antidotes for anti-Xa agents are under development. Activated or non-activated prothrombin concentrates are proposed, although their efficacy to reverse DOAC is uncertain. We propose an update on DOAC-associated bleeding management, integrating the availability of idarucizumab and the critical place of DOAC concentration measurements.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Transfusão de Sangue
/
Antitrombinas
/
Inibidores do Fator Xa
/
Hemorragia
Idioma:
Fr
Revista:
Transfus Clin Biol
Assunto da revista:
HEMATOLOGIA
Ano de publicação:
2017
Tipo de documento:
Article
País de afiliação:
França